This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction value of approximately $732,000, according to a SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($30.38); post-transaction value based on June 25, 2026 market close ($30.40).

1-year price change calculated using June 25, 2026 as the reference date.Continue reading